Poor prognosis of uterine serous carcinoma compared with grade 3 endometrioid carcinoma in early stage patients

Virchows Archiv

Volumn 462, Issue 3, 2013, Pages 289-296

  Park, Ji Young ^a   Nam, Joo Hyun ^a   Kim, Young Tak ^a   Kim, Yong Man ^a   Kim, Jong Hyeok ^a   Kim, Dae Yeon ^a   Sohn, Insuk ^b   Lee, Shin Wha ^a   Sung, Chang Ohk ^a   Kim, Kyu Rae ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Samsung Advanced Institute of Technology (SAIT)   (South Korea)

Author keywords

Endometrial carcinoma; Endometrioid; Grade; Prognosis; Serous

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CLINICAL FEATURE; COMPARATIVE STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TUMOR INVASION; UTERUS CARCINOMA; UTERUS SEROUS CARCINOMA; CANCER STAGING; CYSTADENOCARCINOMA; ENDOMETRIUM TUMOR; KAPLAN MEIER METHOD; META ANALYSIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; UTERUS CANCER;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; UTERINE NEOPLASMS; YOUNG ADULT;

MLCS; MLOWN;

EID: 84876076130     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-013-1382-8     Document Type: Article

References (29)

1. Bray F, Dos Santos SI, Moller H, Weiderpass E (2005) Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol Biomark Prev 14:1132-1142
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917
3. Voss MA, Ganesan R, Ludeman L, McCarthy K, Gornall R, Schaller G, Wei W, Sundar S (2012) Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer - a clinical and pathological evaluation. Gynecol Oncol 124:15-20
4. Cirisano FD Jr, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS, Soper JT, Clarke-Pearson DL (1999) Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol 74:385-394
5. Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15:10-17
6. Zannoni GF, Scambia G, Gallo D (2012) The dualistic model of endometrial cancer: the challenge of classifying grade 3 endometrioid carcinoma. Gynecol Oncol 127:262-263
7. Lax SF (2004) Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 444:213-223
8. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I (2005) Endometrial cancer. Lancet 366:491-505
9. Zannoni GF, Vellone VG, Arena V, Prisco MG, Scambia G, Carbone A, Gallo D (2010) Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study. Virchows Arch 457:27-34
10. Bansal N, Yendluri V, Wenham RM (2009) The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 16:8-13
11. Burton JL, Wells M (1998) Recent advances in the histopathology and molecular pathology of carcinoma of the endometrium. Histopathology 33:297-303
12. Hamilton CA, Cheung MK, Osann K et al (2006) Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 94:642-646
13. Soslow RA, Bissonnette JP, Wilton A, Ferguson SE, Alektiar KM, Duska LR, Oliva E (2007) Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am J Surg Pathol 31:979-987
14. Cirisano FD Jr, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS, Soper JT, Clarke-Pearson DL (2000) The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 77:55-65
15. Boruta DM 2nd, Gehrig PA, Groben PA, Bae-Jump V, Boggess JF, Fowler WC Jr, Van Le L (2004) Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer 101:2214-2221
16. Goldberg H, Miller RC, Abdah-Bortnyak R, Steiner M, Yildiz F, Meirovitz A, Villa S, Poortmans PM, Azria D, Zidan J, Ozsahin M, Abacioglu U, Gold DG, Amit A, Lavie O, Atahan IL, Kuten A (2008) Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). Gynecol Oncol 108:298-305
17. Alektiar KM, McKee A, Lin O, Venkatraman E, Zelefsky MJ, McKee B, Hoskins WJ, Barakat RR (2002) Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer? Int J Radiat Oncol Biol Phys 54:79-85
18. Creasman WT, Kohler MF, Odicino F, Maisonneuve P, Boyle P (2004) Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol 95:593-596
19. Mhawech-Fauceglia P, Herrmann RF, Kesterson J, Izevbaye I, Lele S, Odunsi K (2010) Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium. Eur J Surg Oncol 36:1195-1201
20. Tavassoli FA, Devilee P (2003) WHO classification of tumors: pathology and genetics. Tumors of the Breast and FemaleGenital Organs. IARC Press, Lyon
21. Poulsen H, Taylor CW, Sobin LH (1975) Histologic typing of female genital tract tumors. In: International HistologicClassification of Tumors. No 13. Geneva, Switzerland:World Health Organization
22. Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105:103-104
23. Greggi S, Mangili G, Scaffa C, Scala F, Losito S, Iodice F, Pisano C, Montoli S, Vigano R, Pirozzi G, Giannarelli D (2011) Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study. Int J Gynecol Cancer 21:661-667
24. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557-560
25. Alkushi A, Köbel M, Kalloger SE, Gilks CB (2010) High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int J Gynecol Pathol 29:343-350
26. Bartosch C, Manuel Lopes J, Oliva E (2011) Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features. Adv Anat Pathol 18:415-437
27. Alvarez T, Miller E, Duska L, Oliva E (2012) Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma? Am J Surg Pathol 36:753-761
28. Lax SF, Pizer ES, Ronnett BM, Kurman RJ (1998) Comparison of estrogenand progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation. Hum Pathol 29:924-931
29. Kristensen G, Trope C (2004) Endometrial cancer: the management of high-risk disease. Curr Oncol Rep 6:471-475